Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | ABL1 |
| Variant | E255K |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | ABL1 E255K lies within the protein kinase domain of the Abl1 protein (UniProt.org). E255K demonstrates catalytic efficiency (kcat/km) similar to wild-type Abl1 in an in vitro assay (PMID: 30684523), results in increased autophosphorylation and Stat5 phosphorylation in the context of BCR-ABL1, and has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL (PMID: 15194504), but has not been fully biochemically characterized and therefore, its effect on Abl1 protein function is unknown. |
| Associated Drug Resistance | Y |
| Category Variants Paths |
ABL1 mutant ABL1 E255K |
| Transcript | NM_005157.6 |
| gDNA | chr9:g.130862976G>A |
| cDNA | c.763G>A |
| Protein | p.E255K |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_005157 | chr9:g.130862976G>A | c.763G>A | p.E255K | RefSeq | GRCh38/hg38 |
| NM_005157.5 | chr9:g.130862976G>A | c.763G>A | p.E255K | RefSeq | GRCh38/hg38 |
| NM_005157.6 | chr9:g.130862976G>A | c.763G>A | p.E255K | RefSeq | GRCh38/hg38 |
| NM_007313.3 | chr9:g.130862919G>A | c.763G>A | p.E255K | RefSeq | GRCh38/hg38 |
| NM_007313.2 | chr9:g.130862919G>A | c.763G>A | p.E255K | RefSeq | GRCh38/hg38 |
| NM_007313 | chr9:g.130862919G>A | c.763G>A | p.E255K | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04793399 | Phase Ib/II | Atezolizumab + Bosutinib | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients | Terminated | ESP | 0 |
| NCT04160546 | Phase II | Aspirin + Ponatinib | Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP) (ResToP) | Active, not recruiting | ESP | 0 |
| NCT03874858 | Phase II | Nilotinib Asciminib + Nilotinib | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia (DANTE) | Completed | ITA | 0 |